These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 388737)

  • 21. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
    Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
    Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of pH on the prostacyclin (PGI2) mediated inhibition of platelet function.
    Rao GH; Reddy KR; Hagert K; White JG
    Prostaglandins Med; 1980 Apr; 4(4):263-73. PubMed ID: 6994159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
    Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
    Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergism between prostacyclin (PGI2) and prazosin on human platelet aggregation.
    Moore PK
    Thromb Haemost; 1982 Feb; 47(1):76. PubMed ID: 7041326
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of human platelet aggregation by stable analogs of prostacyclin.
    Togna G; GAndolfi C; Andreoni A; Fumagalli A; Passarotti C; Faustini F; Patrono C
    Pharmacol Res Commun; 1977 Nov; 9(10):909-16. PubMed ID: 343117
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
    Ubatuba FB; Moncada S; Vane JR
    Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergic effect of prostacyclin (PGI2) and alpha-blocking-agent on adrenalin-induced human platelet aggregation.
    Pogliani E; Fantasia R; Colombi M; Praga C
    Thromb Haemost; 1980 Oct; 44(2):106. PubMed ID: 6109380
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anti-platelet aggregation effect of PGI2 potentiated by EG-626].
    Tanaka K; Harada Y; Katori M
    Rinsho Byori; 1979; Suppl 40():188-91. PubMed ID: 399308
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro.
    Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD
    Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of estradiol on platelet aggregation in cerebral microvessels of mice.
    Rosenblum WI; el-Sabban F; Allen AD; Nelson GH; Bhatnagar AS; Choi SC
    Stroke; 1985; 16(6):980-4. PubMed ID: 3937302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prostacyclin on platelet aggregation as studied with "filter-loop" technique in the flowing blood of the dog.
    Imai S; Matsubara I
    Artery; 1980; 8(1):63-72. PubMed ID: 7000043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI2) synthesis in humans and rabbits.
    Ellis EF; Wright KF; Jones PS; Richardson DW; Ellis CK
    J Cardiovasc Pharmacol; 1980; 2(4):387-97. PubMed ID: 6156337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelets from diabetic subjects show diminished sensitivity to prostacyclin.
    Betteridge DJ; El Tahir KE; Reckless JP; Williams KI
    Eur J Clin Invest; 1982 Oct; 12(5):395-8. PubMed ID: 6816610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin-mediated neutralization of platelet antiaggregatory activity of prostacyclin (PGI2): studies on mechanism.
    Saba SR; Saba HI
    Am J Hematol; 1985 Oct; 20(2):97-105. PubMed ID: 3898823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet preservation during cardiopulmonary bypass (CPB) with prostaglandin (PGE1) and prostacyclin (PGI2).
    van den Dungen JJ; Velders AJ; Karliczek GF; Homan van der Heide JN; Wildevuur CR
    Trans Am Soc Artif Intern Organs; 1980; 26():481-6. PubMed ID: 7018057
    [No Abstract]   [Full Text] [Related]  

  • 37. A biphasic effect of prostacyclin (PGI2) on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Thromb Res; 1980 Sep; 19(6):877-81. PubMed ID: 6258262
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans.
    Dembińska-Kieć A; Kostka-Trabka E; Zumda A; Byrska-Danek A; Bierón K; Grodzińska L; Kedzior A; Zelazny T
    Pharmacol Res Commun; 1982 Jun; 14(6):485-98. PubMed ID: 6750655
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole.
    Pickles H; Fish A; Hassan S; Burke C; Warrington S; O'Grady J
    Clin Pharmacol Ther; 1983 Feb; 33(2):178-82. PubMed ID: 6337004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.